THE ROLE OF PHLPP IN PANCREATIC CANCER by Smith, Alena J.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Molecular and 
Cellular Biochemistry Molecular and Cellular Biochemistry 
2015 
THE ROLE OF PHLPP IN PANCREATIC CANCER 
Alena J. Smith 
University of Kentucky, alena.smith.graduate@gmail.com 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Smith, Alena J., "THE ROLE OF PHLPP IN PANCREATIC CANCER" (2015). Theses and Dissertations--
Molecular and Cellular Biochemistry. 24. 
https://uknowledge.uky.edu/biochem_etds/24 
This Doctoral Dissertation is brought to you for free and open access by the Molecular and Cellular Biochemistry at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Molecular and Cellular Biochemistry by 
an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Alena J. Smith, Student 
Dr. Tianyan Gao, Major Professor 
Dr. Michael Mendenhall, Director of Graduate Studies 
 
 
 
 
 
 
 
 
 
 
THE ROLE OF PHLPP IN PANCREATIC CANCER 
 
 
 
 
 
 
DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Medicine 
at the University of Kentucky  
 
 
 
 
 
By 
 
Alena Jeanne Smith 
Lexington, Kentucky 
 
Director: Tianyan Gao 
Associate Professor of Molecular and Cellular Biochemistry 
Lexington, Kentucky 
2015 
 
Copyright © Alena J. Smith 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
THE ROLE OF PHLPP IN PANCREATIC CANCER 
 
 Medicine has come a long way in recent years with reliable treatments for 
many cancers. Pancreatic ductal adenocarcinoma (PDAC) has very few 
treatment options available.  PDAC has a dismal 5 year survival rate of 4% and a 
median survival span of 6 months from point of diagnosis; with a high rate of 
chemotherapy and radiation resistance.  A better understanding of the molecular 
events leading to cancer progression is needed in order to improve the treatment 
and prognosis of PDAC patients. We begin to elucidate the functional importance 
of PHLPP on suppressing progression and metastasis of PDAC. PHLPP belongs 
to a novel family of Ser/Thr protein phosphatases. Our previously published 
studies have demonstrated that PHLPP plays a tumor suppressor role in colon 
cancer by negatively regulating Akt and inhibiting cell proliferation. To determine 
the effect of PHLPP on cell migration and invasion, stable cells were generated 
to knock down or overexpress PHLPP in PDAC cells. The ability of cells to 
migrate and invade was examined using Transwell assays. We found that 
increased PHLPP expression significantly reduced the rate of migration and 
invasion in PDAC cells whereas knockdown of PHLPP had the opposite effect. 
To begin to elucidate the molecular mechanism underlying PHLPP-mediated 
inhibition of migration and invasion in PDAC cells, we discovered that the 
expression level of β4 Integrin was decreased in PHLPP overexpressing cells 
and increased in PHLPP knockdown cells. The increased expression of β4 
Integrin has been shown to promote PDAC development and metastasis, 
although the mechanism leading to β4 Integrin upregulation is less clear. 
Interestingly, we found that the expression of β4 Integrin was highly sensitive to 
PI3K/Akt/mTOR activity in cells in which inhibition of PI3K/Akt/mTOR signaling 
significantly decreased the expression of β4 Integrin. Moreover, the quantitative 
real-time RT-PCR analysis revealed that the mRNA expression of β4 Integrin 
was not altered by changes in PHLPP expression or PI3K/Akt/mTOR activity, 
 
 
thus suggesting a post-transcriptional mechanism. Taken together, these results 
identify a tumor suppressor role of PHLPP in PDAC. Mechanistically, PHLPP 
suppresses PDAC cell migration and invasion by negatively controlling β4 
Integrin expression through its ability to inhibit PI3K/Akt/mTOR signaling. 
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Chapter 1. Introduction 
 
The Pancreas 
The pancreas is a unique organ that is physically situated behind the 
stomach.  The word pancreas itself is derived from the Greek roots “pan” 
meaning “all” and “creas” translated to “flesh” [1]. It is considered part of both the 
exocrine and the endocrine system.  As a glandular organ the pancreas is 
responsible for actions within the digestive system as well as regulating sugar 
homeostasis in the blood.   
The organ itself is around 15-25 cm in length and weighs approximately 
70-150 grams [1, 2]. The head of the organ is “nestled” into the duodenum while 
the body lays behind the stomach and the tail of the pancreas is near the spleen. 
The main pancreatic duct runs the length of the pancreas, combines with the 
common bile duct, and empties its contents into the duodenum through the 
Ampulla of Vater (Figure 1.1) [2]. 
 
Histology of the pancreas 
The pancreas as explained earlier is a unique organ that is both part of the 
exocrine and endocrine system.  In order to achieve this multi-functional and 
duality role for the pancreas the specialized cells of the pancreas must be 
arranged in such a way that it allows for separation of function and 
compartmentalization.  Anatomy of both the exocrine and the endocrine portion 
of the pancreas will be discussed below.  
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Figure 1.1. Anatomy of the pancreas  
The head of the pancreas is nestled into the duodenum while the tail extends 
towards the spleen (adapted from [2]). 
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Exocrine Structure 
The exocrine portion of the pancreas is responsible for aiding in food 
digestion.  In order for the pancreas to complete this task it must release 
digestive enzymes into the duodenum. Without the exocrine function then 
individuals would find themselves in a state of malnutrition [2, 3]. Not only does 
the pancreas secrete digestive enzymes, but also releases ions and water into 
the duodenum as well.  This is important for a few major reasons.  The water 
helps transport the enzymes as well as the food on into the digestive tract and 
the ions help to neutralize the pH of the gastric chyme.  The alkalinity of the 
pancreatic exocrine juices is due to the high concentration (up to 140 mM) of 
NaHCO3 within the secretion.  If the gastric chyme was allowed to maintain an 
acidic pH then the digestive enzymes would lose activity [3].   
The exocrine pancreas consists of the acinus and the draining ducts.  The 
acinar cells drain into the acinus ducts which lead to the interlobular ducts.  The 
interlobular ducts then make way to the main pancreatic ductal system.  The 
acini can be of multiple forms, including spherical, tubular, or an in between form. 
They are tasked with synthesizing, storing, and secreting digestive enzymes.  
The basolateral side houses receptors for both hormones and neurotransmitters 
whereas the apical side contains the zymogen granules with the digestive 
enzymes inside of them [3].   
The centroacinar cell is a unique cell within the pancreas in that it acts as 
a progenitor for different types of cells [3, 4]. Recently, a new cell type called the 
pancreatic stellate cell was discovered in the pancreas.  They are star-shaped 
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cells believed to be responsible for laying down the basement membrane.  These 
stellate cells are currently being investigated for their role in pancreatic cancer 
development [3, 5]. Then we have the ductal epithelial cells, which are 
responsible for the formation of ductal passages within the pancreas as well as 
where the most common form of pancreatic cancer arises from [3].  
The digestive enzymes found within the pancreas are actually capable of 
digesting the very organ that produces them.  Therefore, in order to prevent 
these harmful events mechanisms such as storage in acidic granules have 
evolved [3, 6]. Another such prevention is the synthesis and storage of some of 
these enzymes as precursors.  They are found as proenzymes in the pancreas 
but quickly activate within the duodenum.   This activation occurs when trypsin is 
activated through an enzyme called enterokinase, which removes the N-terminal 
hexapeptide fragment on trypsin.  Trypsin is then free to exert its activity onto the 
proenzymes.  An inhibitor of trypsin called PSTI (Pancreatic Secretory Trypsin 
Inhibitor) is also synthesized in the secretory pathway of the digestive enzymes 
as well as the zymogen granules [3, 6].   
 Amyase is an enzyme that is secreted in both the pancreas and the 
salivary glands.  However, the salivary gland secreted form has a different 
molecular weight and electrophoretic mobility.  This may be attributed to the 
difference in its carbohydrate content.  For both isoforms the enzymatic activity 
remains the same in that they digest both starch and glycogen.  The optimum pH 
for activity is neutral pH but you will find it active in the stomach acid [3, 7].   
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 Another active enzyme called lipase is primarily secreted by the pancreas.  
It is capable of hydrolyzing a triglyceride molecule to two fatty acid molecules 
from carbons 1 and 3.  This hydrolyzing reaction also leads to a monoglyceride 
released with a fatty acid esterified to a glycerol at carbon 2.  The interesting part 
is how the lipase is able to perform its reaction in a water environment when oil 
and water do not mix.  The function of lipase is facilitated by bile acid and 
colipase.  They aid in the binding of lipase to the oil/water interface of triglyceride 
droplets, where lipase exerts its activity [3, 8]. In addition, phospholipases 
hydrolyze fatty acid ester linkage at carbon 2 of phosphatidylcholine [3, 8].   
 Proteases are enzymes that aide in the breakdown of proteins from 
consumed food.  There are two major types of proteases: endopeptidases and 
exopeptidases.  Regardless of type of proteases, all are stored as the proenzyme 
form inside of the zymogen granules.  This keeps them inactive until they are 
deposited in the duodenum where they are activated by trypsin. Interesting 
enough trypsin is an example of endopeptidase as well as chymotrypsin. 
Endopeptidases cleave peptide bonds of proteins internally at specific sites.  
Exopeptidases however cleave 1 amino acid at a time either from the NH2 or 
COOH terminal ends of the protein.  Further digestion of oligopeptides and free 
amino acids occur through the brush-border enzymes.  From there they may be 
transported across the transluminal surface of the small intestine by Na+-H+ 
coupled transporters [3, 9].  
 Some of the inorganic compounds found in the pancreatic secretions into 
the duodenum aren’t just water, but contains many ions: sodium, potassium, 
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chloride, and bicarbonate.  They are just as important in the function of the 
exocrine pancreas as the enzymes themselves. They provide the flow of the 
enzymes from the acinus to the duodenum as well as allowing for the change of 
the pH of the gastric chyme from acidic to neutral [3, 10, 11].   
 In summary, the exocrine pancreas is a beautiful conglomerate of 
cooperative enzymes and compounds that work in cohesive unity to provide 
nourishment for a large and extremely diverse organism.  
 
Endocrine Structure 
The endocrine system is dispersed throughout the exocrine system and 
tissue within the pancreas.  These hormone secreting cells are grouped together 
in little areas referred to as islets, which can be translated to as a small island or 
in anatomy as a distinct portion of tissue surrounded by entirely different tissue.  
Langerhans believed in 1869 that he was seeing intrapancreatic lymph nodes 
[12]. This was later disproven however not only are hormone secreting cells 
present but so are nerve cells as well as the area being highly vascularized [13].   
The islets of Langerhans is the distinct tissue that house the hormone 
secreting cells of the endocrine system within the pancreas.  There are around a 
million islets found in the average pancreas of a healthy adult [13, 14]. Each islet 
measuring around 0.2 mm in diameter is surrounded by a capsule made of 
fibrous connective tissue. There are five major cell types found in the islets: 
alpha, beta, delta, PP, and epsilon [13-15]. The alpha and beta cells in the islet of 
Langerhans play the principle role in regulating blood glucose levels by the 
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coordinated secretion of glucagon and insulin, respectively. The alpha and beta 
cells work in opposition to each other. The activity of alpha cells is stimulated 
during times of hypoglycaemic conditions. Alpha cells secrete glucagon which 
exerts a catabolic effect through activation of glycogenolysis and 
gluconeogenesis within the liver. Compared to the vast knowledge of beta cell 
structure and function little is known about the alpha cells.  This lack of 
knowledge is primarily due to the low concentration of alpha cells within the islets 
and the lack of techniques available for isolation and characterization.  What is 
known is that at low levels of glucose ion channels generate action potentials 
through Na+ and Ca2+.  This electrical activity triggers the release of glucagon. 
When the concentration of glucose rises these events are inhibited. There are 
other mechanisms that glucagon release could be controlled by such as through 
fatty acid exposure but very little is known about these different regulations [13, 
15, 16].   
The beta cells are the most studied and well-characterized cells that 
reside in the islet.  They typically make up the majority of the cell population as 
well.  These hormone producing cells secrete insulin.  In contrast to glucagon, 
insulin activates glycogenesis or the production of glycogen within the liver. 
[Kelly] [Eleyat] [Korc] In beta cells the ATP-sensitive K+ ion channels are open 
while the voltage gated Ca2+ ion channels are closed during resting conditions.  
In response to an increase in glucose concentration, glucose is diffused across 
the membrane into the cell through GLUT2 transporters via facilitated diffusion. 
Glucose undergoes glucose metabolism leads to increased production of ATP.  
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The ATP/ADP ratio changes and as ATP concentration increases it closes the K+ 
ion channels inhibiting the transport of K+ outside of the cell.  As the potassium 
levels rise inside the cell the voltage gated Ca2+ channels are activated allowing 
the calcium ions to cross the cell membrane into the cell [13, 15, 17]. Once inside 
they bind to their respective receptors allowing the insulin containing vesicles 
within the cell to bind to the inside of the cell membrane allowing for the release 
of the insulin through exocytosis [13, 15, 18] (Figure 1.2).   
The delta cells found in the islet of Langerhans in the pancreas produce a 
hormone called somatostatin. One interesting note about somatostatin is that it 
inhibits the function of both the alpha cells and the beta cells.  [[19] Delta cells 
are thought to only affect the adjacent alpha and beta cells. [20]  It is believed 
that somatostatin is either diffused through the interstitium or transported via the 
microvasculature of the islet itself[21]  PP cells are also referred to as the 
Gamma cells and make up an even less population of the islets than the delta 
cells.  PP cells secrete a protein called pancreatic polypeptide or PP.  The 
highest concentration of PP can be found towards the head of the pancreas.  [22] 
PP is believed to regulate appetite and food intake.  It has been found to be of 
lower concentrations after eating but significantly expressed in anorexia nervosa 
patients.  [23]The least abundant cell in the islets is known as the epsilon cell.  
Epsilon cells produce a hormone called ghrelin, which inhibits the release of 
insulin from beta cells within the islets.  It is considered a local regulator of insulin 
just like PP produced by the gamma cells. Ghrelin is being considered as a 
possible target for diabetes treatment.  [24, 25] 
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The information presented above is a brief summary of a simplistic 
overview of the function of the pancreas and it is easy to see how pancreatic 
cancer is so very catastrophic to the individual.  
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Figure 1.2. Insulin secretion in beta cells of the pancreas. 
While in the normal resting state (low glucose) the K+ channel is open allowing 
for the K+ ions to cross the membrane and travel to outside the cell.  As glucose 
concentration increases it is transported through facilitated diffusion by the 
GLUT2 transporter into the beta cell of the pancreas.  From there it goes through 
glucose metabolism which gives the final product of ATP.  As ATP concentration 
increases it binds to the K+ ion channels causing them to close.  Eventually this 
membrane depolarization allows for the Ca2+ channels to open which gives an 
influx of Ca2+ ions.  This leads to the vesicles containing insulin to bind to the cell 
membrane releasing insulin through exocytosis (adapted from [18]).   
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Risk Factors and Pancreatic cancer 
Before we get to the heart of pancreatic cancer we need to look at some 
risk factors. Three major risk factors have the capacity to affect a large majority 
of the American population in various ways: smoking, diabetes, and pancreatitis.  
Looking at the 2013 statistics for smoking in the United States roughly 18 
out of 100 adults smoked which translates to 42.1 million adults who smoke.  
This preventable epidemic kills around 480,000 Americans each year [26]. Since 
the act of smoking doubles the risk of pancreatic cancer and around 20-25% of 
all pancreatic cancers are caused by smoking, it is imperative that the link 
between the two be understood [27]. Other studies have demonstrated that 
smoking increases the expression of oncogenes in specific tissues, such as the 
lung.  This includes mutation in the KRAS gene. As we will see later KRAS is 
found activated in 90% of all pancreatic cancers.  Understanding the mechanism 
on activation of KRAS is also of the utmost importance and it may be linked to 
smoking [28].  However, it should be noted that the majority of studies linking 
smoking to pancreatic cancer has epidemiological [27, 29]. There has been a few 
interesting studies to note that in pancreatic cancer patients who were smokers 
not only did they harbor more mutations but also a larger variety of point 
mutations [29].  
Diabetes mellitus or diabetes is a collection of disorders that give 
enhanced blood sugar levels for a sustained time period [30]. There are three 
major types of diabetes: Type I, Type II, and gestational.  Type I diabetes is due 
to beta cell loss in the pancreas, typically an immune destruction [31]. Type II 
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diabetes is the inability of cells to respond to insulin [32]. Gestational diabetes is 
an interesting case where pregnant women with no previous history of diabetes 
develop high blood sugar [33]. Through a large meta analysis it was discovered 
that 75% of pancreatic cancer patients also carried diabetes mellitus [34]. The 
risk factors for developing pancreatic cancer through diabetes are most likely 
through prolonged insulin exposure. Insulin can regulate cell proliferation as a 
growth hormone.  While in diabetes the cells may become resistant to insulin as 
far as being able to reduce glucose in the blood, the other effects of insulin may 
still be prevalent. Another action of insulin is to decrease the insulin-like growth 
factor binding protein thereby increasing insulin-like growth factor or IGF. IGF is 
an even stronger oncogene than insulin [35]. It is quite easy to understand how 
preventing diabetes or treating it successfully could have an impact on pancreatic 
cancer statistics.  
Pancreatitis is a disorder characterized by inflammation of the pancreatic 
organ.  One interesting aspect of the relationship between pancreatitis and 
pancreatic cancer is the genetic mutations found in pancreatitis is also found in 
pancreatic cancer [36, 37]. Morphological and functional changes within the 
pancreas can be found in chronic pancreatitis patients.  There are some common 
cytokines that are found in both.  These include IL-6, TNF-alpha, IL-8, PDGF, 
and TGF-beta [38]. Another interesting finding is that macrophages which are 
regulators of inflammation and secrete pro-inflammatory cytokines are found 
throughout histological samples of pancreatic cancer as well as pancreatitis [39]. 
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Repeated tissue damage through inflammatory reactions during chronic 
pancreatitis leads to pancreatic cancer formation [39]. 
 
Pancreatic Intraepithelial Neoplasia (PanIN) 
Pancreatic Intraepithelial Neoplasia or commonly referred to as PanIN is 
the step-wise characterization of pancreatic lesions leading into carcinoma.  
PanINs are found to be more common in pancreata histological sections of 
pancreatic cancer patients than in chronic pancreatitis; however, they are more 
prevalent in chronic pancreatitis patients than typical patients [40]. It is important 
to note that there are two other types of lesions found in pancreatic cancer 
patients; however, they are significantly less profound and the PanIN lesions are 
the most common.  The other two lesions are called mucinous cystic neoplasm 
[41] and intraductal papillary mucinous neoplasm (IPMN). Due to the prevalence 
of PanIN lesions we will focus on those [40]. 
PanIN development at each stage has been extensively studied. Common 
gene mutations as well as morphological phenotypical changes have 
characterized and associated with each stage (Figure 1.3) [42, 43]. There are 4 
known stages of PanIN: PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3. PanIN-1A 
and PanIN-1B are considered low-grade lesions that are flat (PanIN-1A) or 
papillary (PanIN-1B) in nature with typical nuclear phenotypes. PanIN-1A is 
considered to have tall columnar cells and can be indistinguishable from non-
neoplastic lesions.  PanIN-1B is basically indistinguishable from PanIN-1A except 
that it is papillary in nature.  PanIN-2 lesions are much more complex with 
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atypical nuclear characteristics including loss of nuclear polarity, nuclear 
crowding, pleomorphism, nuclear pseudostratification, and nuclear 
hyperchromasia.  PanIN-3 lesions are considered carcinoma-in-situ with loss of 
polarity, nuclear atypical, and mitosis. However, PanIN-3 lesions are still found at 
the basement membrane.   
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Figure 1.3. PanIN development.  
There are 4 stages of PanIN: PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3. Each 
PanIN stage is characterized by known mutations within the pancreatic ductal 
cells as well as phenotypic changes. This figure is adapted from Koorstra et al. 
[42]. 
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Many times you can see budding off of small cluster cells, some necrosis, 
and goblet cell irregularities [42-45]. From this point carcinoma develops where 
there is invasion and loss of basement membrane localization. Activation of 
oncogenes such as KRAS and inactivation of tumor suppressors such as SMAD4 
and CDKN2A/INK4A allow tumors to progress from PanIN to carcinoma [46, 47]. 
There have been some recently discovered morphological evidence that 
gives detail as to how these lesions can cause further damage to the pancreas. 
Recently, PanIN lesions have been noted to have lobulocentric atrophy. This 
type of atrophy would be able to decrease acinar cell flow of the secretions 
raising the possibility of a localized inflammatory reaction.  Interesting to note that 
KRAS mutations were found in these samples [48].  
As will be further explained below there have been characterization of the 
genetic changes that occur during PanIN development.  Although a specific order 
has not been determined it does seem that some mutations occur before others, 
such as the activating KRAS mutation is set before the p53 mutation [40].  
Telomere shortening was recently discovered to be present in PanIN-1 lesions.  
This could possibly be used as a histological technique to identify patients with 
chronic pancreatitis who are at risk of developing pancreatic cancer [40]. 
As we have seen genetic alterations that are found in pancreatitis, PanIN 
development and pancreatic cancer protein expression profiles are significantly 
similar between both PanIN lesions and pancreatic cancer. These changes of 
protein expression range from enhanced expression of survivin and adhesion 
molecules.  Mucins are another protein that is expressed in both PanIN type 
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lesions and pancreatic cancer but not other types of pancreata lesions. Mucins 
can be used to distinguish between the different types of lesions and signal to the 
treating physician that the patient has a heightened possibility of developing 
pancreatic cancer [40, 47, 49]. 
 
Genetic alterations in pancreatic cancer 
 There are many risk factors currently known that increase the risk of 
developing PDAC and this includes is but not limited to age, smoking, obesity, 
diabetes, and pancreatitis [50]. An increased risk for developing PDAC can also 
be seen in familial clustering indicating that hereditary gene mutations contribute 
to PDAC development [51, 52]. The Cancer Genome Atlas project has identified 
a number of genetic alterations in human pancreatic cancer. Table 1.1 shows the 
most common mutations that are found in pancreatic cancer. The functional 
contribution of these genetic mutations as well as other genetic alterations in 
pancreatic cancer are discussed in more details below and followed by a 
separate section on KRAS.  
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Gene Chromosome 
Location 
Percentage of 
cancers with a 
mutation  
Type of 
Mutation 
KRAS 12p13 >90% Gain of 
Function 
P16INK4/CDKN2/MTSI 9p21 80% Loss of 
Function 
TP53 17p13 50%-75% Loss of 
Function 
DPC4/SMAD4 18q21 ~50% Loss of 
Function 
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Table 1.1. Common genetic mutations found in pancreatic cancer. 
Pancreatic cancer carries some unique common genetic mutations.  These 
interesting mutations may present a variable chemotherapy treatment target that 
is unique for pancreatic cancer.  
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P16INK4/CDKN2/MTSI genetic variations in pancreatic cancer 
Cyclins, have no intrinsic activity, bind to cyclin-dependent kinases or 
CDKs and target them to subcellular locations as well as help activate them. 
When bound with their respective CDKs the complex is called maturation-
promoting factor [53]. CDKs are serine threonine kinases that regulate the cell 
cycle [54]. Taking it from there inhibitors of CDKs are called cyclin-dependent 
kinase inhibitor proteins or CDKIs or CKIs.  There are two families of CKIs: 
Inhibitors of CDK4 (INK4) and the KIP family.  The INK4 family of CKIs house 4 
members which include p16 (INK4a), p15 (INK4b), p18 (INK4c), p19 (INK4d). 
These 4 members are considered tumor suppressors [55]. The gene for p16INK4 
is referred to as CDKN2.  At another point the protein was also called multiple 
tumor suppressor gene 1 [41]. 
INK4a, found on chromosome 9, can undergo a homozygous deletion, an 
intragenic mutation, and hypermethylation of the promoter [42, 49, 56-58]. The 
INK4a gene arrests the cell between the G1-S phase through binding to CDK4/6 
and inhibiting its action. CDK4/6 binds to cyclin D and becomes an active 
complex that phosphorylates retinoblastoma protein (pRB). Once 
phosphorylated, pRB is able to disassociate from the transcription factor E2F1.  
When E2F1 is freed from pRB it is able to enter into the nucleus and promote 
transcription of genes that promote cell cycle progression. [59] Therefore, 
inactivation of p16 leads to activation of CDK4 and CDK6 and subsequent cell 
cycle progression without the proper checks and balances [55].  It seems that the 
other INK4 proteins (INK4b,c,d) are not involved in the etiology of cancer 
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according to current research [55]. Homozygous deletions of INK4a have been 
found in lymphomas and sarcomas as well as childhood leukemias [60, 61]. 
Hypermethylation of the promoter of INK4a have also been seen in cancers as 
well [62].  
 Mutation of p16 is found in virtually all pancreatic cancers, but also seen 
in the PanINs: 30% PanIN-1A and 1B, 50% PanIN-2, and 71% in PanIN-3 [42, 
63].  It was recently shown that KRAS activation and loss of INK4a locus 
combined can give rise to ductal adenocarcinoma through progression of PanINs 
[64]. They are considered coordinating pathways that promote carcinogensis.  
The coordinating link may be through the relationship of INK4a and constitutively 
active KRASG12V. The KRASG12V is most likely the initiating mutation for pancreatic 
cancer development; however, subsequent deletion of INK4a would confer 
sustained activity of KRASV12 without interference of any attenuating factors 
[65]. Attri et al found that around 80% of pancreatic tumors had some sort of 
INK4a inactivation change.  These changes include the intragenic mutation, 
hypermethylation and homozygous deletion [66]. Future investigations should 
revolve around INK4a and its possible activity and influence on KRAS as well as 
how the different types of INK4a mutations could affect the outcomes of 
pancreatic cancer.  Samples from pancreatitis patients could be evaluated for 
INK4a mutations.  If changes in INK4a were present it would give validation that 
these patients need to be carefully followed for development of pancreatic 
carcinoma.  
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TP53 genetic variations in pancreatic cancer 
 The tumor suppressor p53 (encoded by the TP53 gene) has many roles 
within the cell, but the major role that is exploited in cancer is its role in the arrest 
of the cell cycle at the G1/S phase. Through binding of p53 to a specific p53 
binding site on the promoter of gadd45, it is able to induce transcription.  Once 
GADD45 is transcribed it can interact with PCNA to initiate nucleotide excision 
repair.[67] There are also some other mechanisms in which p53 activates DNA 
repair, but those are quite intensive and not necessary for understanding the 
general role of p53. Apoptosis control is another area of active research 
concerning p53 [68].  
One of the most common genetic mutations found in cancer is actually in 
p53  [69]. Mutations of p53 at an intragenic site coupled with loss of second allele 
occurs in greater than 50% of pancreatic cancers [49]. The typical mutation is 
within the DNA-binding region that contacts the DNA.  These type of mutations 
result in loss of ability for p53 to bind to the DNA and affect transcription of target 
genes [70]. While it is true that mutant p53 is a loss of function events, there is a 
caveat that these mutations may cause p53 to act like a dominant negative and 
exert a type of gain of function.  This was shown when sustained expression of 
p53 lead to increase activation of PDGFRβ (Platelet Derived Groth Factor 
Receptor beta) [71].  The p53 loss of function mutation tends to occur during 
PanIN-3, and again correlates it with a late genetic event [72, 73]. It is interesting 
to note that most of the commonly used pancreatic cell lines all carry p53 
mutations [74].  The focus of studying p53 mutations in pancreatic cancer is to 
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uncover the possibility of new or adjuvant treatments.  While these new 
treatments would most likely require early detection that is why investigation into 
PanIN development from associated with risk factors would provide so useful. 
DPC4/SMAD4 genetic variations in pancreatic cancer   
 SMAD4 a tumor suppressor and downstream signaling event of the 
transforming growth factor β (TGF-β) family, is found mutated in ~50% of 
pancreatic cancers and is a late genetic event like p53 [49, 74].  SMAD4 is 
involved as a co-SMAD that binds to other members of the SMAD family like 
SMAD2.  Together the complex is able to bind to DNA sequences and affect 
transcription of targeted genes.   The most common mutation is homozygous 
deletion, loss of an allele coupled with intragenic mutation.  SMAD4 accumulates 
in the nucleus after TGFβ is stimulated.  SMAD4 functions to check cell cycle 
arrest, and to regulate apoptosis [42]. Patients who had resective surgery did 
significantly better if their tumors expressed wild type SMAD4 [75].  The 5 year 
survival advantage of patients who expressed wild type SMAD4 was determined 
to be approximately 20% whereas only 13% survived to 5 years without SMAD4 
expression.  Although it is currently not known which of SMAD4s activities are 
biologically advantageous what is known that patients have a poorer outcome 
without SMAD4 expression warranting further studies in its activities [75]. 
 Genetic alterations in pancreatic cancer could be used as a histological 
reference in patients who are at risk for developing PDAC.  These high risk 
patients would include pancreatitis patients, diabetic patients, and smokers.  
Going forward in this study we decided to look a little deeper into oncogenic 
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aberrations in pancreatic cancer, specifically events that lead to changes in the 
PI3K/Akt and Raf/MEK/ERK pathways.   
EGFR and HER2/neu amplification in pancreatic cancer 
 The Epidermal Growth Factor Receptor (EGFR) and Her2/neu (ERBB2) 
are transmembrane receptors belonging to the ERBB receptor tyrosine kinase 
family [76]. EGFR and Her2 can function as heterodimers in cells. The ligands for 
EGFR include EGF, TGF-β, amphiregulin, and epiregulin [77]. After ligand 
binding, EGFR activates two well known oncogenic pathways the PI3K/Akt 
pathway and the Raf/MEK/ERK pathway. EGFR-mediated signaling is 
upregulated in many malignancies. This upregulation can come from gene 
amplification or upregulation of EGFRs respective ligands [78]. An activating 
mutation in the kinase domain leads to unchecked activity of EGFR in the 
absence of ligands [79]. The expression of EGFR in the pancreas is typically 
limited to the ductal cells or the Islet of Langerhans.  Overexpression of EGFR is 
found in 40% to 70% of pancreatic cancers and HER2 overexpression in a 
smaller subset of cases [80]. Association of EGFR in pancreatic cancer is found 
in high-grade tumors especially.  Therapeutic strategies aimed at targeting both 
EGFR and Her2 receptors are being developed to treat pancreatic cancer [81-
83]. These therapeutic strategies may prove to be non useful as greater than 
90% of all advanced pancreatic cancer carries the activating KRAS mutation.  
KRAS works downstream of EGFR and other receptor tyrosine kinases.  
Inhibiting EGFR would have little effect on prognosis of advanced patients; 
however, there is always hope as adjuvant treatment [64, 82]. 
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Hedgehog signaling in pancreatic cancer 
It was recently discovered that in approximately 75% of PDAC tumors 
Hedgehog (Hh) signaling is dysregulated, and specifically there is aberrant Hh 
ligand expression [84].  Hh signaling is found in embryonic development where 
different parts of the embryo have different expression of Hh ligands allowing for 
polarity to occur. There are three secreted ligands: sonic hedgehog (SHH), 
Indian hedgehog (IHH), and Desert Hedgehog (DHH).  These Hh ligands signal 
through binding to a receptor called Patched or (PTC); however, without Hh 
ligands PTC binds to Smoothened or SMO and represses its activity. When Hh 
binds to PTC the repression of SMO is released allowing for the Gli nuclear 
family of transcription factors to accumulate. Gli transcription factors activate 
factors that allow for proliferation such as cyclin D and evasion of apoptosis such 
as BCL2 [44, 85]. Activation of Hh signaling promotes PDAC via two different 
mechanisms: i) Hh ligands are over-expressed in the tumor microenvironment, 
which leads to hyperactivation of Hh signaling in the pancreatic tumor cells; and 
ii) there is ligand-independent activation in the tumor epithelium as the result of 
mutations of the signaling molecules (such as PTC) in the Hh pathway. Aberrant 
Hh activity is found throughout the entire PanIN progression and into carcinoma 
[84].    
Wnt/β-catenin signaling in pancreatic cancer 
 The Wnt/β-catenin pathway is used in embryonic development similar to 
Hh signaling. Briefly, Wnt ligands bind to Frizzled receptors which induce 
inactivation of specific cytosolic proteins such as APC that promote β-catenin 
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proteosomal degradation.  Without degradation, β-catenin accumulates in the 
cytosol then translocates to the nucleus where it promotes transcription of 
proteins through binding to TCF/LEF factors [44]. Both cytosolic and nuclear 
accumulation of β-catenin has been observed in pancreatic cancer. Inhibiting β-
catenin through RNAi severely limits proliferative ability of PDAC.  β-catenin 
accumulation in pancreatic cancer may be due to over-expression of Wnt 
ligands, but at this time the mechanism remains poorly understood and it isn’t 
clear which β-catenins targets are important forpancreatic cancer development 
[44, 86]. It is interesting to note is that Wnt signaling appears to be tissue specific 
for example, in melanoma, Wnt inhibits Raf/MEK/ERK signaling, but in both 
colorectal and pancreatic cancer it activates the oncogenic pathway [86].  
Oncogenic signaling mediated by KRAS 
KRAS (Kristen-RAS), a member of the RAS family GTP-binding proteins 
(GTP-ase), is the most commonly mutated oncogene in PDAC. The RAS family 
is known to mediate a large number of important cellular processes such as 
proliferation, cell survival and differentiation.  RAS proteins are not very efficient 
at converting GTP to GDP; therefore, they require a GAP (GTPase Activating 
Protein) such as RasGAP (RASA1) to convert GTP to GDP quickly.   After GTP 
is then hydrolyzed, the nucleotide must be released from KRAS.  A guanine 
nucleotide exchange factor or GEF like Son of Sevenless (SOS) takes over this 
responsibility releasing the GDP to the cytosol and freeing KRAS to bind to 
another GTP. 
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 The most common mutations in KRAS are activating point mutations 
within codon 12.  These point mutations are found in around 30% of early PDAC 
lesions but are present at 95% to 99% of advanced cases of PDAC [50, 87]. The 
activating mutations desensitize KRAS to GAPs or prevent GTP hydrolysis 
resulting in a constitutively active KRAS [87-89]. Activating KRAS mutations 
initiate tumorigenesis by promoting the formation of PanIN lesions, and recently 
murine studies have shown that sustained activation of KRAS is required for 
continued progression of PDAC [90].  
 Activation of KRas leads to sustained activation of key signaling pathways 
within the ductal cells including but not limited to the RAF/ERK/MEK pathway and 
the PI3K/Akt pathway (Figure 1.4). These mitogenic cellular pathways aid in 
crucial oncogenic adaptation such as migratory ability, survival, and increased 
proliferation rate [87].  It has been shown recently that activated KRAS enhances 
the Warburg effect by elevating pancreatic cancers dependence on aerobic 
glycolysis.  This metabolic reprogramming is most likely through the activation of 
PI3K/Akt pathway and its effector proteins such as HK1, Glut1, and Pfk1 [91]. 
Changes in the microenvironment in pancreatic cancer are directly linked to 
activated oncogenic KRAS as well. Continued inflammatory onslaught to the 
pancreas and the immune system activation induces fibrotic and inflammatory 
remodeling of the pancreas, which leads to prolonged activation of KRAS [92]. 
To treat KRAS mutant tumors, combinatorial treatment that inhibits both PI3K/Akt 
and MEK/ERK would likely be needed [90]. 
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Figure 1.4. RAS-mediated activation of both Raf/MEK/ERK and PI3K/Akt 
pathway.  
This illustration shows the ability of RAS activate both Raf and PI3K two major 
oncogenic pathways in pancreatic cancer. Activating KRas mutations allows for 
sustained activation of both pathways. This figure is adapted from Mohseni et al. 
[93].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
The role of integrin in pancreatic cancer 
In order for cells, regardless of type, to migrate they must sustain a 
transient interaction between themselves and the substrate to which the cells 
adhere to in order to undergo migration. Even transients interaction between the 
cell and the substrate is the workings of a consensus of proteins and protein 
complexes [94]  One of the proteins involved are the Integrins.  Integrins are 
transmembrane receptors consisting of α and β heterodimers that are capable of 
binding the extracellular matrix (ECM) and linking to the intracellular actin 
network of the cell [95]. Examples of ECM proteins include laminin, fibronectin, 
and collagen.  Integrins are found distributed in migrating cells in a polarized 
manner, in that increased integrin clustering is found at the leading edge of the 
cell where PIP3 levels rise as PI3K activity increases leading to adhesion 
formation [94].   
 It was recently discovered that α6β4-integrin expression is markedly 
increased in PDAC, with a step-wise increase in expression through PanIN and 
on into carcinoma [96-98]. Integrins not only function as adhesion molecules that 
promote migration, but also activate both PI3K/Akt and Raf/MEK/ERK oncogenic 
pathways [99, 100]. Integrins activate FAK and SFK proteins upon outside in 
activation. This is achieved upon binding of integrins to one of its ligands found in 
the ECM (Figure 1.5). The activation of FAK leads to activation of PI3K which in 
turn promotes phosphorylation and activation of Akt. SFK proteins activate SHC 
which leads to downstream activation of Raf/MEK/ERK and proliferation signals 
[101].  
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Figure 1.5. Integrin activation leads to activation of PI3K/Akt and 
Raf/MEK/ERK pathways. 
Integrin activation leads to cell proliferation, survival, and migration through 
activation of multiple oncogenic pathways. This figure is adapted from Guo et al. 
[101]. 
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The tumor suppressor role of PHLPP  
 PHLPP (PH domain leucine-rich-repeats protein phosphatase) belongs to 
a novel family of Ser/Thr protein phosphatases that consists of PHLPP1 and 
PHLPP2 isoforms. Two splice variants of PHLPP1, PHLPP1α and PHLPP1β, 
have been reported, of which PHLPP1β contains an in-frame extension at the N-
terminus of PHLPP1α (Figure 1.6) [102, 103]. PHLPP1 has first been proposed 
as a regulator of circadium rhythm as the mRNA expression of PHLPP1 in the rat 
brain suprachiasmatic nucleus region varies in a circadian-dependent manner. 
Thus, it was initially named SCOP for suprachiasmatic nucleus circadian 
oscillatory protein [104]. Overexpression of PHLPP1β in mouse forebrain impairs 
memory formation in transgenic mice by inhibiting ERK signaling [105]. 
Importantly, Gao et al. identified PHLPP as the novel protein phosphatase that 
directly dephosphorylates Akt and turns off Akt-mediated growth and survival 
signaling (Figure 1.7) [106]. PHLPP is then renamed based on its domain 
structure as it contains a PH domain, a leucine rich repeat region, a phosphatase 
domain, and a PDZ ligand motif (Figure 1.6) [106, 107].  
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Figure 1.6. Domain structures of PHLPP1 and PHLPP2 isoforms. 
Both PHLPP isoforms contain a PH domain, a leucine rich repeat region (LRR), a 
phosphatase domain (PP2C-like phosphatase domain), and a PDZ ligand motif. 
Total numbers of amino acids are labeled for each isoform. 
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Figure 1.7. PHLPP-mediated dephosphorylation and inactivation of Akt.  
Activation of Akt requires membrane translocation and phosphorylation at both 
T308 and S473 sites. This PI3K-dependent activation of Akt can be prevented by 
PTEN, a lipid phosphatase, which removes the activation signal. PHLPP 
inactivates Akt by directly dephosphorylating Akt protein. 
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Increasing evidence has indicated that both PHLPP isoforms serve as 
tumor suppressors in different types of cancer, which include colorectal, lung, 
liver and pancreatic cancer [108-111]. It has been shown that PHLPP negatively 
regulates multiple oncogenic pathways by directly dephosphorylating and 
inactivating key signaling molecules, such as Akt, S6K, and RAF1 [106-108, 112-
114]. Moreover, PHLPP promotes the degradation of conventional PKCs by 
dephosphorylating the hydrophobic motif of PKC [115]. One interesting caveat is 
that Akt is part of this feedback loop with S6K, in which S6K-mediated 
phosphorylation of IRS at Ser-302 prevents the association of IRS with IGFR and 
downregulates IRS protein, thus, preventing activation of Akt following IGFR 
activation [116]. PHLPP also regulates the negative feedback loop of Akt by 
dephosphorylating S6K and decreasing its activity [113].  
PHLPP is frequently downregulated in colorectal cancer patients and 
reintroduction of PHLPP into colon cancer cells inhibits cell proliferation, in vitro, 
and tumorigenesis in nude mice [108]. Recently, Li et al. demonstrated that 
PHLPP is a negative regulator of the RAS/RAF pathway by directly 
dephosphorylating RAF1 and inhibiting its kinase activity. Knockdown of PHLPP 
enhances signaling through the RAF/MEK/ERK cascade, induces EMT, and 
increases cell migration and invasion [117]. Genetic deletion of PHLPP1 
promotes the development of invasive intestinal adenocarcinoma and decreases 
survival in ApcMin mice [117]. In pancreatic cancer, PHLPP expression is reduced 
in PanIN lesions compared to normal controls, and is almost entirely lost in 
PDAC tissues [118]. 
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This correlates with increasing phosphorylation of Akt through different 
PanIN stages to PDAC [118]. Collectively, PHLPP provides a balance in both 
Raf/MEK/ERK and PI3K/Akt pathways; and loss of PHLPP leads to aberrant 
activation of these pathways giving rise to cells that are able to proliferate 
unchecked while having an increase in ability to migrate (Figure 1.8).  
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Figure 1.8. PHLPP plays a pivotal role in controlling the signaling balance 
of both PI3K/Akt and RAS/RAF pathways. 
These two oncogenic pathways, PI3K/Akt and Raf/MEK/ERK pathways, are 
exploited during turmorigenesis and metastasis.  PHLPP is a converging point 
that regulates both. 
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Significance of this study 
 Increasing numbers of studies have indicated that PHLPP plays an 
important role in turning off major oncogenic signaling pathways [119]. The 
majority of these studies have focused on colorectal cancer and revolved around 
the oncogenic kinase Akt.  Recent studies show PHLPP not only regulates the 
activity of the PI3K/Akt pathway, but also has the ability to inhibit the 
Raf/MEK/ERK pathway by dephosphorylating RAF1. These two pathways play 
central roles in PanIN lesion development and especially PDAC formation, and 
close to 95% of PDAC metastatic tumors are found to have active KRAS 
mutations.  Given the extremely low survival rates of pancreatic cancer, new 
diagnostic and treatment strategies are urgently needed in order to improve 
patient survival in pancreatic cancer.   
 In this study, we investigated how the change in expression of PHLPP 
regulated PI3K/Akt and RAF/MEK/ERK signaling in PDAC cells. We discovered 
that PHLPP negatively regulates the migratory ability of PDAC.  After differing 
PHLPP levels of expression in pancreatic cancer cells we noticed that α4β6 
integrin expression was significantly altered. This may be through PHLP 
regulating the lysosomal mediated degradation pathway of integrins.  Our study 
establishes a novel link between PHLPP, Akt, and integrin. Better understanding 
of how PHLPP functions as a tumor suppressor and the underlying molecular 
mechanism may help to identify new therapeutic targets in pancreatic cancer.   
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Chapter 2. Methods and Materials 
 
Cells and reagents 
The following pancreatic ductal adenocarcinoma cell lines, ASPC-1, Panc-
1, and Suit-2, were kindly provided by Dr. Kathleen O’Connor (University of 
Kentucky).  The Panc-1 cells used in this study were sorted for their high integrin 
expression as described previously [120]. Panc-1 cells were cultured in DMEM 
whereas ASPC-1 and Suit-2 cells were cultured in RPMI-1640. All media were 
supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich) and 1% 
penicillin/streptomycin.  
The shRNAs for human PHLPP1, PHLPP2, AKT1 and AKT2 genes used 
in this study were constructed in pLKO.1-puro vector and purchased from Sigma-
Aldrich [121]. The targeting sequences are as the following: PHLPP1, 5’-
CGAGGTCTTTCCCGAAGTTAT-3’, PHLPP2, 5’- 
GCCTGAACTTGTCCCATAATA-3’, AKT1, 5’-GGACAAGGACGGGCACATTAA-
3’ and AKT2, 5’- CCCTTAAACAACTTCTCCGTA-3’. A plasmid carrying a non-
targeting sequence was used to create the control cells. For virus packaging, the 
control or gene-specific shRNA constructs were co-transfected with psPAX2 and 
pMD2.G packing plasmids (Addgene) into 293T cells using polyethylenimine 
(PEI). The virus containing media were collected, filtered, and overlaid onto 
pancreatic cells in the presence of polybrene (8 μg/ml). The infected cells were 
then subjected to selection with puromycin (1 μg/ml). To overexpress human 
PHLPP1 or PHLPP2, the retroviral expression plasmids, including pBabe-puro-
HA-PHLPP1β and pBabe-puro-HA-PHLPP2, were described previously [108, 
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114]. The stable PHLPP overexpressing cells were generated by infecting cells 
with retrovirus encoding HA-PHLPP1β or HA-PHLPP2 and selecting with 
puromycin (1 μg/ml). 
PHLPP1 and PHLPP2 antibodies were obtained from Proteintech and 
Bethyl Laboratories, respectively. The phospho-Akt (p-Akt for the Ser473 site), 
phospho-ERK1/2 (p-ERK for Thr202/Tyr204), phospho-MEK1/2 (p-MEK for 
Ser217/221), EGFR and E-cadherin antibodies were from Cell Signaling. The 
vimentin antibody was from BD Biosciences whereas the γ-tubulin antibody was 
from Sigma-Aldrich. The following integrin antibodies were used in this study: for 
Western blotting, anti-β1 rabbit mAb (D2E5, Cell Signaling) and anti-β4 mouse 
mAb (clone 7, BD Biosciences); and for blocking ECM binding, anti-β1 mouse 
mAb (clone 6S6, Millipore) and anti-β4 mouse mAb (clone ASC-8, Millipore). The 
following chemicals, including PI3K inhibitor LY290042, rapamycin, PP242 and 
Akt inhibitor VIII, were purchased from EMD/CalBiochem. The MEK1/2 inhibitor 
PD0325901 was purchased from Selleck Chemicals, and lysosome inhibitors 
bafilomycin A1 and cycloheximide were from Sigma-Aldrich.  
 
Immunoblotting 
Cultured cells were harvested and lysed in Lysis Buffer (50 mM Na2HPO4, 
1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton 
X-100, 1 mM DTT, 200 mM benzamidine, 40 mg ml-1 leupeptin, 200 mM PMSF) 
and the detergent-solublized cell lysates were obtained after centrifugation for 5 
minutes at 16,000 g at 4 oC. Equal amounts of cell lysates as determined by 
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Bradford assays were resolved by SDS-PAGE and subjected to immunoblotting 
analysis. The density of ECL signals was obtained and quantified using a 
FluoChem digital imaging system (Alpha Innotech). 
 
Wound Healing Assay 
Cultured cells were plated in a 6 well plate in their respective media.  
Using a 200uL pipette tip a wound was made through the center of each well.  
The cells were washed with cold 1XPBS three times to rinse away any non-
attached cell.  The plate was placed in the incubator for 24 hours.  Pictures were 
taken at time 0 and at 24 hours.  The diameter of the wound was measured at 
time 0 and time 24 hours.  The percent wound healed was calculated by 
migration of the cells closing the gap or wound.   
 
Transwell migration assays 
Serum starved pancreatic cancer cells were seeded into the upper 
chamber of Transwell inserts with an 8-m pore size membrane (Corning). For 
migration assays, the bottom of the inserts were coated with collagen (15 g/ml) 
or laminin (25 μg/ml), and the cells were allowed to migrate towards media 
containing either HGF (20 ng/ml) or IGF-1 (20 ng/ml) in the lower chamber for 2-
5 hours.  At the end of the incubation period, Transwell inserts were fixed in 
methanol and stained with 0.5% crystal violet. The numbers of cells that were 
migrated to the lower chamber of the Transwell were counted using an inverted 
microscope at 20X magnification. 
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Time-lapse live cell imaging and analysis 
Stable control and PHLPP overexpressing Panc-1 cells and PHLPP 
knockdown ASPC-1 cells were serum starved for 2 hours and seeded as single 
cells onto collagen (15 g/ml) or laminin (25 g/ml) coated glass bottom culture 
dishes (MatTek). The migration of live cells was recorded in media containing 
HGF (20 ng/ml) using Nikon BioStation IM equipped with CO2 incubation 
chamber. Time-lapse phase images were taken either every 5 or 10 minutes for 
6 hours with a 20X objective. The movement of cells was tracked and analyzed 
using Nikon Element AR software. 
 
3D cell culture 
Single cell suspension of pancreatic cancer cells was prepared in serum 
free media and embedded into collagen/Matrigel (1:1) mixture. The cells were 
overlaid with 2% Matrigel in 2% FBS containing media. The cells were allowed to 
grow into cyst-like structures in the 3D matrix for 1-2 weeks. The size and 
morphology of the cysts were examined by phase-contrast microscopy using a 
Nikon Ti-E inverted microscope. For immunofluorescence staining, the cysts 
were fixed in 4% paraformaldehyde and permeabilized using 1% Triton X-100 in 
PBS. Actin was stained using Alexa 488-conjugated phalloidin while the nuclei of 
the cells were stained with DAPI-containing mounting medium. Cells were 
visualized using an Olympus FlowView FV1000 confocal laser-scanning 
microscope.  
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Immunofluorescence (IF) staining 
IF staining was performed following procedures described previously 
[122]. Briefly, stable control and PHLPP overexpressing Panc-1 cells and PHLPP 
knockdown ASPC-1 cells were serum starved for 2 hours and seeded as single 
cells onto collagen (15 g/ml) coated coverslips and allowed to attach for 20 
minutes. The cells were then fixed in 4% paraformaldehyde and followed by 
incubating with labeling buffer (1% bovine serum albumin in phosphate-buffered 
saline, pH 7.4) to block nonspecific binding. In labeling buffer the antibody 
specific for anti-β4-integrin antibody from BD biosciences was diluted and added 
to the cells for 2 hour incubation.  The cells were then washed 3 times for 5 
minutes each wash with 1XPBS.  Alexa 488-conjugated phalloidin and Alexa 594 
fluorescent dye were diluted in labeling buffer and incubated with the cells for 1 
hour. The basolateral distributions of F-actin were visualized using a Nikon laser 
TIRF (Total Internal Reflection Fluorescence) microscope. 
 
Real-time PCR 
Total RNA was isolated with RNeasy kit (Qiagen) from different stable 
pancreatic cancer cell lines. Equal amounts of RNA were used as templates for 
the synthesis of cDNA using High Capacity cDNA Reverse Transcription kit 
(Applied Biosysems). Real-time PCR reaction was performed using the StepOne 
Real-Time PCR system (Applied Biosysems) with β1- and β4-specific probes. All 
values were normalized to the level of β-actin. 
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Statistical Analysis 
The results from the experiments to assess the rate of migration, levels of 
protein and mRNA expression, cell growth in 3D, and velocity and distance 
migrated by single cells were summarized using mean ± SEM or mean ± SD. All 
experiments were performed in triplicate and pairwise comparisons were carried 
out using two-sample t-tests. Statistical significance of values among different 
groups was set at p < 0.05.  
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Primer: Designation: Sequence: 
CD29 (Igβ1) 
Forward 
β1-Integrin Primer TGACCATCTCTTCTCCTCTCCAC 
CD29 (Igβ1) 
Reverse 
β1-Integrin Primer GGAGTCACACTGGTCAACAGAG 
CD104 (Igβ4) 
Forward 
Β4-Integrin 
Primer 
AAAAAGGATTGAGTTCCTTGCAAAAA 
CD104 (Igβ4) 
Reverse 
Β4-Integrin 
Primer 
CCCAGAGTCTTGTGGTTCTCTAAC 
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Table 2.1: Primers used for qRT-PCR 
Primers for both β4 integrin and β1 integrin were used in qRT-PCR studies. 
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Chapter 3 
 Results 
 
Introduction 
 Accumulation of genetic mutations in oncogenes and tumor suppressors 
lead to the development of pre-malignant lesions which eventually through 
genetic instability give rise to carcinoma within the pancreatic ductal epithelium 
[123]. Thus, a better understanding of the molecular events leading to cancer 
progression is needed in order to improve the treatment and prognosis of PDAC 
patients.  Key mutations in oncogenes such as KRAS with deactivation of tumor 
suppressor genes SMAD4 and CDKN2A/INK4A have been implicated in the 
development and progression of pancreatic cancer [47, 124]. In addition, it has 
been shown that overexpression of integrin α6β4 promotes migration and 
invasion of pancreatic cancer cells and is associated with the progression of 
PDAC [97, 120]. Integrins are known to contribute to tumor progression and 
metastasis by directly activating a number of oncogenic signaling pathways, 
including PI3K/Akt and RAS/RAF pathways, in various types of cancer [99, 100]. 
However, the molecular mechanism by which the expression of integrin proteins 
is regulated remains elusive in pancreatic cancer cells.  
PHLPP (PH domain leucine-rich repeat protein phosphatase) belongs to a 
novel family of Ser/Thr protein phosphatases. There are two isoforms, PHLPP1 
and PHLPP2, identified in this family [102, 103, 106, 107]. Both PHLPP isoforms 
were first discovered as the phosphatases for Akt that directly dephosphorylate 
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the hydrophobic motif Ser473 site and inactivate the kinase [106, 107]. Moreover, 
it has been shown that PHLPP dephosphorylates Ser338, a key activation site on 
RAF1, and inhibits the downstream signaling through RAF/MEK/ERK in colon 
cancer cells [114]. Therefore, PHLPP may exert its tumor suppressor function by 
negatively regulating both the PI3K/Akt and RAS/RAF pathways. Recently, 
Nitsche et al discovered that there is a stage-dependent downregulation of 
PHLPP in pancreatic cancer patient specimens, thus suggesting a tumor 
suppressor role of PHLPP in pancreatic cancer [111]. However, it remains 
unknown whether loss of PHLPP expression promotes cancer cell migration in 
pancreatic cancer. 
 In this study, we investigated the effect PHLPP expression had on cell 
migration and motility in pancreatic cancer cells.. We identified a novel 
connection between PHLPP expression and integrin function. Results from our 
study revealed that PHLPP-loss increases cell motility by upregulating integrin 
expression and inducing EMT. Furthermore, this regulation of integrin expression 
mediated by PHLPP may be through lysosomal degradation of integrin, 
specifically β4 and β3 integrin. 
 
PHLPP negatively regulates the activity of Akt and MEK/ERK in pancreatic 
cells 
To determine if PHLPP negative regulates both the PI3K/Akt and 
Raf/MEK/ERK pathway in human pancreatic cancer, we established stable cell 
lines overexpressing PHLPP1 or PHLPP2 in Panc-1 cells, which express very 
 
56 
 
low levels of endogenous PHLPPs. The PHLPP1 gene potentially encodes two 
differentially spliced variants, PHLPP1α and PHLPP1β [102]. Since the longer 
transcript of PHLPP1, PHLPP1β, is the predominant form expressed 
endogenously in all pancreatic cell lines examined, we used PHLPP1β in our 
study. We first determined the effect of PHLPP overexpression on cell signaling. 
As shown in Figure 3.1, both Akt and MEK/ERK activity were downregulated in 
PHLPP overexpressing cells compared to control cells as indicated by decreased 
phosphorylation of Akt, MEK, and ERK. Next, to determine the effect of 
endogenous PHLPP on inhibiting Akt and MEK/ERK signaling, PHLPP was 
silenced in ASPC-1 cells, which express relatively higher levels of endogenous 
PHLPPs, using lentiviral-mediated RNAi. Immunoblotting results revealed that 
phosphorylation of Akt, MEK, and ERK was significantly elevated when PHLPP 
expression was knocked down (Figure 3.2). Consistent with previous reports on 
the tumor suppressor function of PHLPP in other cancer types [108, 114, 125-
127], our results here provide the initial evidence that PHLPP is capable of 
inhibiting both Akt and MEK/ERK signaling in pancreatic cancer cells.  
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Figure 3.1. Overexpression of PHLPP isoforms inhibits PI3K/Akt and 
MEK/ERK signaling.  
(A) Stable control, HA-PHLPP1β or HA-PHLPP2 overexpressing Panc-1 cells 
were generated using retrovirus-mediated infection. The cell lysates were 
prepared and analyzed for phosphorylation and total protein expression by 
immunoblotting. (B) Relative phosphorylation for p-Akt, p-MEK, p-ERK were 
calculated and normalized to those of total Akt, MEK and ERK, respectively.  The 
level in control cells was set to 1. Data represent the mean ± SEM (n=3, * p<0.05 
by two-sample t-tests).   
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Figure 3.2. Loss of PHLPP expression enhances PI3K/Akt and 
RAF/MEK/ERK signaling.  
(A) Stable control (sh-Con) and PHLPP knockdown (sh-PHLPP1 and sh-
PHLPP2) ASPC-1 cells were generated using lentivirus-mediated RNAi. The cell 
lysates were analyzed for phosphorylation and total protein expression by 
immunoblotting. (B) Relative phosphorylation for p-Akt, p-MEK, p-ERK were 
calculated and normalized to those of total Akt, MEK and ERK, respectively.   
The level in control cells was set to 1. Data represent the mean ± SEM (n=3, * 
p<0.05 by two-sample t-tests).  
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PHLPP negatively regulates cell migration in pancreatic cancer cells  
Previous studies of PHLPP expression in colorectal cancer cells showed 
an enhanced ability for PHLPP knockdown cells to migrate and transition into 
EMT [114]. To test if PHLPP regulates cell motility in pancreatic cancer cells, we 
first examined the expression of EMT markers in PHLPP overexpressing Panc-1 
and PHLPP knockdown ASPC-1 cells. As shown in Figure 3.3, PHLPP 
overexpression markedly increased the expression of E-cadherin, an epithelial 
cell marker, and decreased the expression of vimentin, a mesenchymal cell 
marker. Conversely, knockdown of either PHLPP isoform decreased E-cadherin 
whereas increased vimentin expression (Figure 3.3), suggesting that PHLPP 
downregualtion promotes EMT in pancreatic cancer cells.  
  To begin the initial study of migration in pancreatic cancer we investigated 
the ability of PHLPLP overexpressing Panc-1 cells to heal a wound introduced 
into the cultured cells.  Figure 3.4 shows the significant difference in ability of the 
PHLPP overexpressing cells to close the gap after the wound was introduced 
compared to the control cells.  By 24 hours post scratch the control pancreatic 
cancer Panc-1 cells had healed the wound by 90% but the PHLPP 
overexpressing cell lines had about a 40-45% gap closure.  This was the first hint 
that PHLPP could influence the migratory ability of pancreatic cancer cells.   
  Furthermore, to determine if PHLPP regulates pancreatic cancer cell 
migration. PHLPP overexpressing Panc-1 cells and PHLPP knockdown ASPC-1 
cells were subjected to Transwell migration assay. We found that PHLPP 
overexpressing cells migrated significantly slower than the control cells as 
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determined by Transwell migration assays (Figure 3.5). In contrast, knockdown 
of PHLPP significantly enhanced the ability of pancreatic cancer cells to migrate 
in response to HGF. Similar results were obtained when using IGF-1 and 
collagen were used as chemoattractants (Figure 3.6). Taken together, we have 
identified a role of PHLPP in inhibiting EMT and cell motility in pancreatic cancer 
cells. 
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Figure 3.3.  Knockdown of PHLPP expression induces EMT phenotype in 
pancreatic cancer cells.  
Cell lysates were prepared from stable control and PHLPP overexpressing Panc-
1 as well as PHLPP knockdown ASPC-1 cells.  The expression levels of E-
cadherin and vimentin were analyzed using immunoblotting. 
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Figure 3.4. PHLPP inhibits the ability of pancreatic cancer cells to heal a 
wound. 
Panc-1 cells were plated in a 6-well plate, a wound was introduced by scratching 
the cells off using a 200uL pipette tip.  The diameter of the wound was measured 
at time 0 and 24 hour.  Each experiment was done in duplicates and three 
independent experiments were averaged and expressed as mean  SEM (* 
p<0.05 by two-sample t-tests compared to the control cells). 
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Figure 3.5. PHLPP negatively regulates pancreatic cancer cell migration. 
Stable control and PHLPP overexpressing Panc-1 cells and stable control and 
PHLPP knockdown ASPC-1 cells were subjected to Transwell migration assays 
using HGF and laminin as chemoattractants. The inserts shown were 
representative images of cells migrated in the Transwell assays. Each 
experiment was done in duplicate and three independent experiments were 
averaged and expressed as mean  SEM (* p<0.05 by two-sample t-tests 
compared to the control cells). 
  
 
69 
 
 
  
 
70 
 
Figure 3.6. Migration of pancreatic cancer cells is amplified when PHLPP 
expression is lost. 
Stable control and PHLPP knockdown ASPC-1 cells were subjected to Transwell 
migration assays using either HGF and collagen (A) or IGF-1 (20 ng/ml) and 
laminin (B) as chemoattractants.  Each experiment was done in duplicate and 
three independent experiments were averaged and expressed as mean  SD (* 
p<0.05 by two-sample t-tests compared to the control cells). 
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 We next determined the effect of PHLPP on modulating cell motility at the 
single cell level. To this end, PHLPP overexpressing Panc-1 and PHLPP 
knockdown ASPC-1 cells were subjected to cell tracking experiments to monitor 
the cell movement in real time. The Biostation allows for pictures to be taken at 
specific intervals, which then can be used to track each individual cells migration. 
Stable control and PHLPP overexpressing or knockdown cells were seeded on 
glass-bottom plates coated with laminin, starved, then stimulated with HGF.  We 
found that overexpression of PHLPP resulted in a significant decrease in cell 
motility when compared to control cells (Fig. 3.7A). The velocity and average 
distances traveled were significantly decreased in PHLPP overexpressing cells 
as well (Fig. 3.7B-C). To determine the effect of silencing the endogenous 
PHLPP expression at the single cell level, similar experiments were performed 
using control and PHLPP knockdown ASPC-1 cells. We found that PHLPP 
knockdown cells were considerably more motile (Fig. 3.8), and the velocity and 
average distances traveled were significantly increased in PHLPP knockdown 
cells (Fig. 3.8B-C). Taken together with results obtained in Transwell migration 
assays, we showed that PHLPP expression negatively impacts single cell 
migration and velocity. Since increased motility is often associated with increased 
aggressiveness in order for pancreatic cancer cells to metastasize, our data 
provide evidence supporting the tumor suppressor role of PHLPP.   
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Figure 3.7. PHLPP inhibits cell motility at the single cell level.  
(A) Migration patterns of stable control and PHLPP overexpressing Panc-1 cells 
on laminin coated plates using HGF as the chemoattractant. The trajectories of 
12 randomly chosen cells for each cell line were plotted in the graphs. (B-C) The 
average distance traveled (B) and the relative velocity (C) of 12 stable control 
and PHLPP overexpressing Panc-1 cells during 6 hours of migration. Data 
represent mean  SD (n = 12 cells/line, * p<0.05 by two-sample t-tests).  
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Figure 3.8. Knockdown of PHLPP increases cell motility at the single cell 
level.  
(A) Migration patterns of stable control and PHLPP knockdown ASPC-1 cells on 
laminin coated plates using HGF as the chemoattractant. The trajectories of 12 
randomly chosen cells for each cell line were plotted in the graphs. (B-C) The 
average distance traveled (B) and the relative velocity (C) of 12 stable control 
and PHLPP knockdown ASPC-1 cells during 6 hours of migration are shown. 
Data represent mean ± SEM (n = 12 cells/line, * p<0.05 by two-sample t-tests).   
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PHLPP inhibits the invasive growth of pancreatic cancer cells in 3D culture 
EMT requires the process of cancer cells sending extensions away from 
the cell body in order to migrate. To further determine the effect of PHLPP on 
invasive growth of pancreatic cancer cells, we used 3D cell culture systems as 
they closely mimic the cancer microenvironment and they provide a better 
opportunity to explore the effects of oncogenes and tumor suppressors on 
modulating morphogenesis as well as invasive growth [128, 129]. Both PHLPP 
overexpressing Panc-1 and PHLPP knockdown ASPC-1 cells were seeded into 
Matrigel and allowed to grow for up to 7 days. The control Panc-1 cells grew into 
large multi-globular clusters with spikes of membrane protrusions extending into 
Matrigel (Figure 3.9A-B). However, the formation of membrane protrusions was 
completed blocked in PHLPP overexpressing cells and the size of cell clusters 
was significantly decreased.  (Figure 3.9C)   
Although no clear membrane protrusions were observed in ASPC-1 cells 
grown in Matrigel, PHLPP knockdown cells formed significantly larger globular 
clusters compared to the control cells, suggesting that PHLPP-loss increases the 
invasive growth ability of pancreatic cancer cells (Figure 3.10) 
In addition, TIRF (Total Internal Reflection Fluorescence) imaging was 
incorporated into our studies to look at formation of stress fibers, extensions, and 
integrin expression.  Control Panc-1 cells showed the formation of both stress 
fibers and long filamentous extensions at the basolateral membrane surrounding 
the entire cells whereas very few actin stress fibers were observed in PHLPP 
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overexpressing cells (Figure 3.11).  Integrin staining in PHLPP overexpressing 
cells seems to be located more centrally to the cell possibly closer to the nucleus 
of the cell instead of at the extensions compared to control.  The reduction of 
integrin expression at the extensions and protrusions could possibly negatively 
affect migration and cell motility.  However, when ASPC-1 cells were stained for 
both actin and integrin it is apparent that there are major filamentous extensions, 
large protrusions from the basolateral membrane surrounding the cells and the 
most interesting aspect is the large amount of integrin staining at the basolateral 
membrane and protrusions (Figure 3.12).  ASPC-1 control cells have nice actin 
stress ring formation and integrin staining inside of the stress ring, but still in 
punctate formation (Figure 3.12), unlike the Panc-1 overexpressing cells where 
the integrin staining is more diffuse and less punctate (Figure 3.11). In the 
ASPC-1 PHLPP knockdown cells integrin staining is most noticeable at the 
protrusions and filamentous extensions seen coming from the basolateral 
membrane.  The β4-integrin staining is punctate in pattern and seems to be 
deposited outside of the cell membrane giving a unique arrangement (Figure 
3.12). Collectively, these results showed that decreased PHLPP expression 
alters actin cytoskeleton rearrangement and increases invasive growth of 
pancreatic cancer cells. 
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Figure 3.9. PHLPP inhibits the invasive phenotype of pancreatic cancer 
cells grown in 3D culture.   
Stable control and PHLPP overexpressing Panc-1 cells were seeded in Matrigel 
and allowed to grow for 7 days. On the 3rd day (Top panel) and the 7th day 
(Bottom panel) after seeding phase contrast images were taken with the 10X 
objective on using an inverted Nikon microscope. The boxed regions were 
enlarged and shown next to the original images. Scale bars, 100 μm. (C) The 
size of cell clusters at day 7 was measured and analyzed using Nikon Element 
AR software. Data represent mean ± SEM (n = 18 cells/line, * p < 0.05 by two-
sample t-tests). 
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Figure 3.10. Knockdown of PHLPP promotes the invasive growth of 
pancreatic cancer cells in 3D culture.  
Stable control and PHLPP knockdown ASPC-1 cells were seeded in Matrigel and 
allowed to grow for 7 days. On the 5th day (A) and the 7th day (B) after seeding 
phasecontrast images were taken with the 10X objective on using an inverted 
Nikon microscope. Scale bars, 100 μm. (C) The size of cell clusters at day 7 was 
measured and analyzed using Nikon Element AR software. Data represent mean 
± SEM (n = 18 cells/line, * p < 0.05 by two-sample t-tests). 
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Figure 3.11. PHLPP affects actin cytoskeleton dynamic in pancreatic cancer 
cells. 
Stable control and PHLPP overexpressing Panc-1 cells were seeded onto 
collagen coated cover slips in serum-free media. After 20 minutes of incubation 
at 37oC the cells were fixed with 4% paraformaldehyde, blocked with anti-goat 
serum, incubated with β4-integrin antibody, and stained with Alexa488-phalloidin 
and Alexa 594 anti-mouse dye. TIRF images were from the basolateral 
membrane of the cells and two representative images are shown for each cell 
line (scale bars, 20 μm).  
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Figure 3.12. Knockdown of PHLPP affects integrin localization in pancreatic 
cancer cells.  
Stable control and PHLPP overexpressing Panc-1 cells were seeded onto 
collagen coated cover slips in serum-free media. After 20 minutes of incubation 
at 37oC the cells were fixed with 4% paraformaldehyde, blocked with anti-goat 
serum, incubated with β4-integrin antibody, and stained with Alexa 488-phalloidin 
and Alexa 594 anti-mouse dye. TIRF images were from the basolateral 
membrane of the cells and two representative images are shown for each cell 
line (scale bars, 20 μm).  
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PHLPP regulates the expression of integrin in pancreatic cancer cells 
Previous studies have shown that increased β4 integrin expression is 
associated with pancreatic cancer progression [97]. Interestingly, when 
examining the expression of β integrin using Western blotting analysis, we found 
that the expression of both β4 and β1 integrin was significantly reduced in PHLPP 
overexpressing Panc-1 cells, suggesting that increased expression of PHLPP 
suppresses integrin expression. On the other hand, knockdown of PHLPP in 
ASPC-1 cells results in a significant increase in the expression of both β4 and β1 
integrin (Figure 3.13).  
To further determine if PHLPP-mediated regulation of β4 and β1 integrin 
expression is controlled at the transcriptional level, total RNAs were isolated from 
PHLPP overexpressing Panc-1 and PHLPP knockdown ASPC-1 cells, and 
quantitative real-time PCR (qRT-PCR) analysis was performed using probes 
specific for the β4 or β1 integrin gene. The results revealed that the mRNA levels 
of β4 and β1 integrin were not significantly altered by changes in PHLPP 
expression (Figure 3.14). Interestingly, the mRNA expression of β1 integrin was 
increased in PHLPP1β overexpressing cells. However, since the expression of β1 
integrin protein was decreased, this increase in mRNA expression unlikely 
contributes to PHLPP induced downregulation of β1 integrin. Collectively, these 
results indicated that PHLPP negatively regulates integrin expression via a post-
translational mechanism in pancreatic cancer cells. 
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Figure 3.13. Integrin protein expression inversely changes in regard to 
PHLPP expression.  
(A) Cell lysates prepared from PHLPP overexpressing Panc-1 and PHLPP 
knockdown ASPC-1 cells were analyzed for the expression of β1 and β4 integrin 
and tubulin using immunoblotting. (B-C) Relative expression of β1 (B) and β4 
integrin (C) was calculated and normalized to tubulin.  The level in control cells 
was set to 1. Data represent the mean ± SEM (n=3, * p<0.05 by two-sample t-
tests).   
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Figure 3.14. Integrin mRNA expression is not altered relative to PHLPP 
expression.  
Total RNAs were isolated from PHLPP overexpressing Panc-1 cells (A) and 
PHLPP knockdown ASPC-1 cells (B). Quantitative real-time PCR analysis was 
performed using probes specific for human β1 and β4 integrin genes. Each 
experimental point was done in triplicates, and the graphs represent the mean ± 
SD (n=3).  
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Figure 3.15.  EGFR protein expression mirrors integrin protein expression 
in response to PHLPP activity. 
Cell lysates prepared from PHLPP overexpressing Panc-1 and PHLPP 
knockdown ASPC-1 cells were analyzed for the expression of EGFR, PHLPP1, 
PHLPP2 and tubulin using immunoblotting.  
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Interestingly, we found that not only was integrin expression altered when 
PHLPP expression was changed so was EGFR (Figure 3.15).  EGFR is an 
oncogene that is commonly activated in many cancers including pancreatic 
cancer [77, 79, 81-83].  Activation of EGFR in pancreatic cancer can also be 
achieved via increased secretion of EGFR ligands by the tumor cells themselves 
[83]. Co-localization of EGFR with integrin has been reported in the lipid rafts 
suggesting common mechanisms may control the protein expression of both 
EGFR and integrins [130]. 
To further investigate the mechanism by which PHLPP regulates integrin 
expression, we tested if the PI3K/Akt or the MEK/ERK pathway is involved in 
controlling the expression of integrin proteins. Inhibiting the PI3K/Akt pathway 
using a PI3K inhibitor, LY294002, in ASPC-1 cells resulted in an approximately 
40% reduction in both β4 and β1 integrin expression over time (Figure 3.16A-B). 
PP242, an inhibitor of PI3K and mTOR, is able to reduce integrin expression in 
ASPC-1 cells. However, this was not seen when rapamycin, an mTOR inhibitor, 
was used to treat the pancreatic cancer cells (Figure 3.16 C).  Similar decrease 
of integrin expression was seen in cells treated with an Akt inhibitor, Akt-VIII 
(Figure 3.16D). In contrast, treating cells with a MEK inhibitor, PD325901, did 
not alter the expression of integrin (Figure 3.17A), suggesting that PHLPP-
induced downregulation of integrin is likely mediated through inhibition of Akt 
signaling. As a control, we found that the mRNA levels of integrin were not 
significantly changed in cells treated with LY294002 (Figure 3.17B). 
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To further validate the influence that PI3K/Akt pathway has over integrin 
expression, we stably knocked down either Akt1 or Akt2 in ASPC-1 cells.  In Akt 
knockdown cells both β4 and β1 integrin expression was greatly reduced 
compared to control (Figure 3.18). Just as seen previously in PHLPP 
overexpressing cells (Figure 3.15), EGFR protein expression was markedly 
reduced in Akt knockdown pancreatic cancer cells. Interestingly, knockdown of 
Akt induced mesenchymal-epithelial transition (MET), the reverse process of 
EMT, in ASPC-1 cells as indicated by increased E-cadherin and decreased 
vimentin expression. Similar results were observed in PHLPP overexpressing 
cells (Figure 3.3). Taken together, our findings suggested that PHLPP negatively 
regulates β4 and β1 integrin expression likely through inhibition of Akt activity in 
pancreatic cancer cells. 
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Figure 3.16. Inhibition of PI3K/Akt pathway decreases integrin expression.  
(A) ASPC-1 cells were incubated with LY294002 for 0-12 hours. At indicated time 
points, cell lysates were prepared and analyzed for the expression of β1 and β4 
integrin and tubulin using immunoblotting (B) Relative expression of β1 and β4 
integrin at different time points following LY294002 treatment in ASPC-1 cells 
was calculated and normalized to tubulin. The level in untreated cells was set to 
1. Data represent the mean ± SEM (n=3, * p < 0.05 by two-sample t-tests). (C) 
ASPC-1 cells were incubated with PP242 or rapamycin for 0-12 hours. At 
indicated time points, cell lysates were prepared and analyzed for the expression 
of β1 and β4 integrin and tubulin using immunoblotting.  (D) ASPC-1 cells were 
incubated with AKT VIII, LY294002, and Rapamycin for 8 hours. Cell lysates 
were prepared and analyzed for the expression of β4 integrin, p-AKt, and tubulin 
using immunoblotting.  
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Figure 3.17. The effect of inhibiting PI3K/Akt and MEK/ERK signaling on the 
expression of integrins in pancreatic cancer cells.  
(A) ASPC-1 cells were treated with DMSO, LY294002 or PD0325901 for 16 
hours. Cell lysates were prepared and analyzed for the expression of β4 integrin 
and tubulin using immunoblotting. (B) Panc-1 cells were treated with LY204002 
(20 nM) for 4 or 8 hours and total RNAs were extracted. Real-time PCR analysis 
was performed using probes specific for human β4 integrin gene. Each 
experimental point was done in triplicates, and the graphs represent the mean ± 
SD (n=3).  
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Figure 3.18. Knockdown of Akt decreases the expression of integrin in 
pancreatic cancer cells.  
Cell lysates prepared from sh-control, sh-Akt1 and sh-Akt2 ASPC-1 cells were 
analyzed for the expression of β1 and β4 integrin. The expression of EGFR, 
pERK, E-cadherin, vimentin and tubulin was also analyzed using immunoblotting. 
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Blocking integrin activity inhibits PHLPP-loss induced increase in cell 
motility 
  To determine the functional impact of PHLPP-mediated inhibition of 
integrin expression, we examined the rate of cell migration in control and PHLPP 
knockdown ASPC-1 cells in the presence of blocking antibodies against β4 or β1 
integrin. As shown in Figure 3.19A, incubating cells with either β4 or β1 integrin 
blocking antibodies significantly reduced cell migration in both control and 
PHLPP knockdown cells as measured by Transwell assays. Moreover, inhibiting 
integrin activation impaired cell motility at the single cell level as the relative 
velocity in the control and PHLPP knockdown cells became indistinguishable 
after the blocking antibody treatment (Figure 3.19B). These data suggested that 
increased integrin expression in PHLPP knockdown cells is responsible for 
increased cell migration. 
We then assessed the ability of Akt knockdown ASPC-1 cells to migrate in 
response to HGF. Surprisingly, Akt knockdown cells had enhanced migratory 
ability when compared to control cells (Figure 3.20). This paradoxical effect of 
Akt on cell migration has been reported in breast cancer cells in which Akt-
mediated inhibition of NFAT activity has been indicated as the underlying 
molecular mechanism [131, 132]. In addition, when treating Akt knockdown cells 
with β1-integrin blocking antibody, the ability of control cells to migrate was 
significantly inhibited as described in Figure 3.19. However, the β1-integrin 
blocking antibody was unable to block migration of Akt knockdown cells (Figure 
3.20). Interestingly, we found the activation of ERK was increased in Akt 
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knockdown cells (Figure 3.20). This activation of ERK may mediate the integrin-
independent effect of silencing Akt on cell migration in pancreatic cancer.   
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Figure 3.19. The PHLPP-mediated regulation of cell migration relies on its 
ability to control integrin expression.  
(A) Stable control and PHLPP knockdown ASPC-1 cells were subjected to 
Transwell migration analysis using HGF as the chemoattractant. To block integrin 
activation, ASPC-1 cell suspensions were incubated with blocking antibodies of 
β1 or β4 integrin in serum-free media containing 1% BSA for 20 minutes at 4 °C. 
The cells were then seeded onto the collagen coated Transwells in the presence 
of the blocking antibodies and allowed to migrate for 4 hours at 37°C. Each 
experiment was done in duplicate and three independent experiments were 
averaged and expressed as mean  SEM (* p<0.01 by two-sample t-tests 
compared to the control cells). (B) Cells as treated as above with blocking 
antibodies were monitored for single cell motility using time-lapse imaging. The 
cells were allowed to migrate in response to HGF for 6 hours. The average 
velocities of 12 cells from each group are shown. Data represent mean ± SEM (n 
= 12 cells/line, * p<0.05 by two-sample t-tests).   
 
 
 
 
 
 
 
 
 
105 
 
 
 
  
 
106 
 
Figure 3.20.  The effect of Akt knockdown on cell migration in pancreatic 
cancer cells.  
(A) Stable control and Akt knockdown ASPC-1 cells were subjected to Transwell 
migration assays using HGF as chemoattractant. To block integrin activation, 
ASPC-1 cell suspensions were incubated with the β1 integrin blocking antibody in 
serum-free media containing 1% BSA for 20 minutes at 4 °C. The cells were then 
seeded onto the collagen coated Transwells in the presence of the blocking 
antibodies and allowed to migrate for 4 hours at 37°C. Each experiment was 
done in duplicate and three independent experiments were averaged and 
expressed as mean  SEM (* p<0.01 by two-sample t-tests compared to the 
control cells). (B) Cell lysates prepared from control and Akt knockdown ASPC-1 
cells were analyzed using immunoblotting. 
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Integrin expression is controlled through lysosomal degradation in 
pancreatic cancer cells 
Recent studies have suggested that integrins can be internalized upon 
binding to extracellular matrix (ECM) ligands and trafficked to lysosome for 
degradation [133-136]. To determine if decreased integrin expression seen in 
PHLPP overexpressing cells is due to increased lysosomal degradation, we 
incubated control and PHLPP overexpressing Panc-1 cells in NH4Cl containing 
media. The presence of NH4Cl, a lysosomotropic alkalinizing agent, inhibits 
lysosomal protein degradation. Indeed, both β4 and β1 integrin expression 
increased in response to lysosome inhibition with NH4Cl (Figure 3.21). At the 
end of 8-hour treatment, the expression of β4 and β1 integrin in PHLPP 
overexpressing cells was similar as that of the control cells (Figure 3.21). Similar 
results were obtained in cells treated with different lysosome inhibitors, 
Bafilomycin A1 and chloroquine (Figure 3.21). Taken together, we showed that 
inhibition of lysosome-mediated protein degradation rescues the integrin 
expression in PHLPP overexpressing pancreatic cancer cells. 
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Figure 3.21. Inhibiting lysosomal degradation pathway gives enhanced 
expression of integrin.  
(A) Stable control and PHLPP overexpressing Panc-1 cells were treated with 
NH4Cl (5 mM) for 2, 4, and 8 hours. Cell lysates were prepared and analyzed by 
immunoblotting for integrin expression. (B) Stable control and PHLPP 
overexpressing Panc-1 cells were treated with Bafilomycin A (BA) or Chloroquine 
(CQ) for 4 hours.  Cell lysates were prepared and analyzed by immunoblotting for 
β4 integrin expression.  
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Chapter 4. Discussion and Future Directions 
  
PHLPP functions as a negative regulator of cell migration in pancreatic 
cancer. 
A number of recent studies have provided strong evidence suggesting that 
PHLPP serves as an important tumor suppressor in various cancer types [103, 
106-108, 125, 126, 137]. For example, it has been shown that PHLPP is 
downregulated in colon cancer patients and decreased PHLPP expression 
promotes tumor growth as the result of increased activation of both PI3K/Akt and 
RAS/RAF oncogenic signaling [103, 108, 114]. Similarly, reduced PHLPP 
expression has been reported in pancreatic cancer patient specimens and re-
expression of PHLPP1 in pancreatic cancer cells induces cell death and inhibits 
tumorigenesis [111]. However, the role of PHLPP in regulating cell migration has 
not been determined in pancreatic cancer. Here we show that PHLPP plays an 
important role in influencing cell motility. Specifically, overexpression of either 
PHLPP isoform decreases cell migration whereas knockdown of endogenous 
PHLPPs significantly enhances cell motility in pancreatic cancer cells. The role of 
PHLPP in pancreatic cancer has been supported by the results obtained from 
wound healing assay, transwell assay, and single cell motility assays.  Moreover, 
the level of PHLPP expression regulates the ability of pancreatic cancer cells to 
grow in 3D culture.  This effect can be seen in both the knockdown and 
overexpressing pancreatic cells.  Knockdown PHLPP ASPC-1 cells have 
significantly larger cluster formation; whereas, overexpressing PHLPP in Panc-1 
cells significantly inhibits the formation of large clusters.  Instead these Panc-1 
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overexpressing PHLPP pancreatic cancer cells have a much reduced cluster size 
compared to control as well as loss of filamentous extensions and protrusions 
from the cell and cluster. This PHLPP-mediated inhibition of cell growth and 
migration coincides with inhibition of both Akt and MEK/ERK activation. In our 
study, the effect of PHLPP on regulating cell motility in pancreatic cancer cells is 
not isoform specific, with either PHLPP1 or PHLPP2 overexpression is able to 
inhibit cell migration whereas knockdown of either isoform results in a similar 
increase in cell motility.  This lack of isoform specificity is also seen in regarding 
to the changes in EMT phenotype of pancreatic cancer cells. In Panc-1 cells 
overexpressing either isoform results in enhanced expression of E-cadherin and 
loss of vimentin.  E-cadherin is an epithelial cell marker whereas vimentin is 
considered a mesenchymal cell marker. Loss of E-cadherin and gain of vimentin 
are the phenotypes associated with EMT and increased migratory potential. The 
enhanced EMT phenotype is shown in stable PHLPP knockdown ASPC-1 cells 
when compared to control. Pancreatic cancer is extremely aggressive and can 
quickly become metastatic. It is important to find new chemotherapy targets that 
are unique to pancreatic cancer.  PHLPP’s ability to influence EMT and migration 
of pancreatic cancer is likely related to its regulation of integrin degradation. 
Reduced integrin expression at the cell membrane may impair lamellopodia 
extension and adhesion to the ECM that are required for cell migration. Taken 
together, our findings establish a novel link connecting PHLPP downregulation 
with enhanced integration function in pancreatic cancer. 
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Regulation and functional implication of integrin trafficking 
In this study, we show that PHLPP plays a novel role in altering integrin 
expression.  Since varying PHLPP expression, meaning overexpression of 
PHLPP in Panc-1 cells or treating cells with PI3K/Akt inhibitors such as AktVIII 
and LY294002, has no effect on decreasing the mRNA levels of integrins, 
PHLPP may regulate integrin expression via a post-translational mechanism. Our 
findings that PHLPP overexpression and treating cells with PI3K/Akt inhibitors 
result in a similar decrease in β1 and β4 integrin expression suggest that reduced 
Akt activity is likely the molecular mechanism underlying PHLPP-mediated 
downregulation of integrins. Indeed, knockdown of either Akt1 or Akt2 
significantly decreases both β1 and β4 integrin expression. Furthermore, using 
lysosome inhibitors we find that the expression of both β1 and β4 integrins 
increase significantly, rescuing the effects of PHLPP overexpression in Panc-1 
cells.  Whereas, treating cells with a proteasome inhibitor MG-132 has no effect 
on rescuing β1 and β4 integrin expression in PHLPP overexpressing cells.  This 
gives the first hint that the point of influence for PHLPP may be in allowing for 
integrin degradation instead of endosomal recycling. Another interesting finding 
is that EGFR protein expression is altered in response to changes of PHLPP 
expression levels to a similar extent as the integrin protein expression. When 
PHLPP is overexpressed, EGFR protein expression is reduced or inhibited 
compared to control; however, when PHLPP is lost through a stable knockdown 
mechanism EGFR protein expression is increased. When lysosome inhibitors are 
used to treat pancreatic cancer cells there is an enhanced expression of integrin 
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compared to untreated cells, and lysosomal inhibitors are able to rescue the loss 
of integrin expression in PHLPP overexpressing cells. These results suggest that 
PHLPP may regulate integrin expression by promoting lysosomal-mediated 
degradation of integrin proteins. Previous studies have supported the notion that 
of lysosome plays a major role in mediating degradation of integrin [133, 134, 
138, 139]. If PHLPP can enhance integrin lysosomal degradation then cell 
motility may be halted therefore providing a new possible therapeutic target to 
prevent metastasis of pancreatic cancer.   
The cell surface delivery and endocytosis of integrins are dynamically 
regulated processes and are fundamental for cell migration in wound healing and 
during cancer cell metastasis [138, 140]. Like many cell surface receptors, 
integrins are known to undergo endo/exocytic cycles, in which they are 
internalized, trafficked through endosome, and then recycled back to the plasma 
membrane [100, 139-141]. This recycle process occurs rather efficiently as the 
degradation rates of integrins are generally very slow [136, 142]. However, 
recent studies reveal that ligand-bound integrins can be ubiquitinated and sorted 
to lysosome for degradation by the ESCRT pathway [136, 143]. Preventing 
lysosome-mediated degradation of integrins increases recycling of integrins to 
the plasma membrane and enhances integrin-mediated cancer cell migration and 
invasion [139, 141]. It was recently discovered that sorting nexin 17 binds to the 
free cytoplasmic tail of β1-integrin while in the endosome preventing its 
degradation and allowing for endosomal recycling [144]. Endosomal recycling of 
cell surface receptors and integrins is a major process that may confer EMT and 
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aggressiveness of cancer. The ability of cancer cells to recycle receptor tyrosine 
kinases (RTKs) and integrins allow them to effectively and efficiently produce 
extensions that allow for migration [138]. It has been suggested that oncogenic 
mutations in EGFR may allow for the receptors to evade lysosomal degradation 
and promote tumor progression [138].  Accepted beliefs in EGFR signaling 
include that the majority of signaling occurred at the plasma membrane and is 
attenuated through endosomal internalization of the receptor.  However, this was 
recently challenged when it was demonstrated that signaling can still occur after 
internalization from the actual endosomes [145]. Oncogenic mutations in EGFR 
lead to sustained activation even when there is a large deletion of the 
extracellular domain.  This gives a constitutively active protein with less ability to 
be silenced through internalization [145]. It is a possibility that when EGFR and 
integrin reside in the same lipid raft that these types of mutations in EGFR could 
lead to reduction of internalization of integrin and allowing for sustained signaling 
through integrin itself by keeping it in the active conformation [146]. In addition, 
there is evidence supporting a physical interaction between EGFR and integrins, 
which would provide another mechanism for coordinated control of EGFR and 
integrin protein expression [147]. 
Promotion of lysosome-dependent degradation of integrins, has been 
shown previously, by activating PI3K/Akt signaling which enhances integrin 
recycling to the plasma membrane in a GSK-3β-dependent manner. GSK-3β 
phosphorylates kinesin light chain and inhibits the activity of kinesin. This leads 
to inhibition of endosomes trafficking through the microtubules and subsequent 
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maturation into late endosomes and merging with the lysosomes [148].  One 
assay that could be performed to determine the potential involvement of GSK-3β 
is to determine the phosphorylation of GSK-3β in PHLPP overexpressing Panc-1 
cells and PHLPP knockdown ASPC-1 cells.  It has been shown recently that 
GSK-3β and Akt are associated with Appl endosomes, a subpopulation of early 
endosomes [149]. It is possible that the close association of Akt and GSK-3β 
allows for Akt-mediated phosphorylation and subsequently inactivation of GSK-
3β. In pancreatic cancer, activation of Akt as the result of PHLPP-loss would lead 
to inactivation of GSK-3β and allow integrins to bypass lysosomal-mediated 
degradation and remain membrane bound. Using integrin recycling assays, we 
would be able to look at integrin recycling under various settings, such as PHLPP 
overexpressing cells, PHLPP knockdown cells, Akt knockdown cells, activation of 
the PI3K/Akt pathway via stimulation with growth factor receptor ligands, and 
inhibition of the PI3K/Akt pathway using inhibitors. This assay will allow us to 
directly assess how integrin expression at the plasma membrane is regulated by 
PHLPP and PI3K/Akt signaling.  
At this moment our data suggests the involvement of PI3K/Akt pathway on 
regulating integrin expression, but our data is limited to using the inhibitor 
approach. Since the pancreatic cancer cells used in our study contain a genetic 
background of activated mutant KRas which allows for sustained and prolonged 
activation of both the PI3K/Akt pathway and the Raf/MEK/ERK pathway, it is a 
possibility of using dominant negative proteins downstream of KRas that would 
provide a mechanism to tease out the role that each pathway plays.  We are able 
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to silence Akt and we can use shRNA to knockdown function of Raf/MEK/ERK or 
we can overexpress a dominant negative form of Raf1 which would help in 
terminating the Raf/MEK/ERK signaling pathway [150]. A dominant negative form 
of ERK could also be used to create a situation where the pathway is terminated 
further down the cell signaling cascade.  This was investigated in human 
pancreatic cancer cell lines and it was discovered that expression of dominant 
negative ERK lead to reduced survival of pancreatic cancer cells in colony 
formation studies [151]. Using these approaches we could further elucidate either 
the PI3K/Akt pathway or the Raf/MEK/ERK pathway is responsible for altering 
integrin protein expression. These additional studies are needed in order to 
provide a complete picture for future therapeutic targets.   
Another role Akt may play in integrin expression is through direct 
phosphorylation.  It has been shown that Akt phosphorylates both β3 and β1 
integrins tail thereby allowing adhesion molecules to interact with their tails 
keeping them forcefully anchored within the cell membrane [152, 153]. It is 
interesting that β4 integrin carries the longest tail out of all of the integrins and 
would allow for direct Akt phosphorylation. Future experiments can be performed 
to replace endogenous β4 integrin with a mutant β4 integrin that lacks the 
cytoplasmic tail. Comparing the effect of PHLPP on regulating the expression of 
mutant integrin with the wild-type integrin will allow for further elucidation of the 
molecular mechanism by which PHLPP controls the expression of integrins.  
Using TIRF microscopy as shown in Figure 3.11-3.12 we can determine if 
mutant β4 and β1 integrin are better retained at the basolateral membrane.  As in 
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Figure 3.12 the staining of integrin is punctate and may coincide with recycling 
endosomes.  This can also be viewed through TIRF imaging by looking at co-
localization of integrin with recycling endosomal marker Rab11 [154]. There is 
evidence suggesting that PHLPP is associated with the plasma membrane or the 
endosomal membrane [126, 155]. Using TIRF we could demonstrate the 
possibility of a physical interaction between PHLPP and integrin at the plasma 
membrane or the endosomal level. PHLPP has a PH domain that has been 
shown to bind PIP3.  PIP3 is also found on endosomes therefore providing 
another possible link between PHLPP and integrin [156].   
In a previous study an ARF GAP called ACAP1 was shown to be targeted 
to recycling endosomes in order to sort cargo leading either to lysosomal 
degradation or allowed to recycle to the plasma membrane.  Li et al 
demonstrated that ACAP1 is required for integrin endosomal recycling and co-
localizes at recycling endosomes.  When cells are stimulated, most likely this 
would be when integrin binds to its respective ligand or there’s stimulation 
through an RTK, integrins (such as β1 integrin) are sent to be recycled through 
recycling endosomes. ACAP1 associates with β1 integrin at the recycling 
endosomes interface. Akt associates with ACAP1 and phosphorylates its Ser554 
residue.  This allows ACAP1 to sort the internalized endosomes cargo such as 
integrin into recycling endosomes so it can be re-associated with the plasma 
membrane [157]. This provides another mechanism linking Akt activation to 
integrin recycling. It is possible that when PHLPP is downregulated, activated Akt 
leads to phosphorylation of ACAP1 which allows the internalized integrins to be 
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sorted into the recycling endosome instead of continuing its degradation path to 
the lysosome. Future studies can determine the phosphorylation of ACAP in 
PHLPP overexpressing and knockdown cells. In addition, ACAP1 can be 
silenced using RNAi in PHLPP knockdown where Akt is continuously active to 
evaluate its involvement. Co-localization of ACAP1, Akt, and integrin in 
pancreatic cancer cells with the endosomal recycling marker Rab11 can also be 
performed.  These studies will provide additional mechanistic insight into integrin 
recycling.  
This PHLPP-mediated regulation of integrin recycling process likely has a 
broader implication in the trafficking of membrane receptors. One interesting 
observation in our study is that not only is integrin expression changed in 
response to PHLPP expression, but also is EGFR a known RTK that is degraded 
through the lysosomal pathway. It would not be surprising if EGFR and integrin 
as well as other growth factor receptors and adhesion molecules use some of the 
same mechanisms in order to regulate their lysosomal degradation and 
endosomal recycling pathways. Using some of the same machinery would be 
efficient and provide a unique way to regulate very intricate multi-step processes. 
Thus, PHLPP represents a novel regulator of cell motility by possibly controlling 
the balance of integrin recycling and degradation, as well as other RTKs, in 
pancreatic cancer cells. 
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Integrin and invadosomes 
Integrins are believed to be found in the “invadosomes” when it comes to 
migration or adhesion signaling especially in cancer [158]. Invadosomes are 
structures in invasive cells that are similar to podosomes in structure and 
function. It has been known for some time that integrins have two different 
conformations, low and high affinity conformations, which may allow them to 
sense the outside environment or particular ECM [159]. Essentially the 
interaction between integrin and ECM proteins connects the motility of the cell to 
the environment both internal and external [158]. Although a number of studies 
have indicated β3 integrin as the major regulator of invadosome formation 
because of its co-localization with the invadosome structures [160, 161], β3 
integrin deficient cells are still capable of forming invadosomes [162]. Additional 
studies show that β1 but not β3 integrins are required for invadosome formation 
and stabilization; and the activation state of β1 has been linked to the integrin-
mediated degradation of ECM [162, 163]. It has been suggested that actin 
bundles are grouped together with integrins and the ECM substrates to create 
the invadosomes (Figure 4.1) [162]. 
There are some novel concepts that allow for these invadosomes to 
become predominantly explored in the future of cancer and especially pancreatic 
cancer research.  One such interesting concept is that metallomatrix proteins are 
used by the invadosomes to promote degradation of the ECM to allow for the 
invadopodia and invadosome formation in cancer cells [164]. In addition, it has 
been shown not only pancreatic cancer cells but the cancer-associated 
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fibroblasts (CAFs) can form invadosomes as well.  One study demonstrates that 
high expression of palladin in CAFs promotes the formation of invadosomes and 
invadopodia, which are responsible for creating channels in the ECM for 
pancreatic cancer cells to invade and metastasize through tumor stroma [165].  
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Figure 4.1.  The invadosome and its components. 
The invadosome is comprised of many components with the major players being 
integrins, receptors, the lipid membrane, actin, talin, and other proteins and 
structures of the cell. This figure is adapted from Albiges-Rizo et al. [166].   
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Interestingly, Neel et al. have discovered that KRAS mutation by itself was 
sufficient to induce invadopodia formation in pancreatic cancer cells. However, 
activation of the RAF/MEK/ERK pathway is not required to form the invadopodia 
whereas treating cells with inhibitors of the PI3K/Akt pathway blocks the 
formation of invadopodia [167]. This finding supports our results that PHLPP-
dependent downregulation of integrin expression is mediated by Akt inactivation 
and inhibition of the PI3K/Akt pathway in pancreatic cancer cells. Enhanced 
activation of Akt in PHLPP knockdown cells may sustain the expression of 
integrin via continual recycling of integrins to the membrane. Given the role of 
integrin in promoting invadosome formation, loss of PHLPP may enhance the 
invasive growth of pancreatic cancer cells through invadosomes and invadopodia 
formation. To support this hypothesis, we find that the expression of integrin is 
mainly localized at the cell extensions in PHLPP knockdown ASPC-1 cells as 
detected by TIRF microscopy (Figure 3.11-3.12).  The vesicle-like staining 
patterns of integrins may reflect the recycling of integrins that are associated with 
invadosome through the endosomes along the actin bundles.  Future studies are 
needed to further test the hypothesis that Akt activity is involved in regulating the 
trafficking and recycling of integrins and to elucidate how integrins are 
internalized from the invadosomes through the endocytic pathway and sorted for 
lysosomal degradation.   
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Conclusions 
While our study provides the first glimpse of PHLPP as a tumor 
suppressor in pancreatic cancer as a regulator of migration through possible 
control of integrin expression and degradation, more studies are needed to 
extend our findings. To determine the functional significance of PHLPP in vivo, 
we can take advantage of PHLPP1 and PHLPP2 knockout mice. It will be 
important to investigate if PHLPP-loss promotes pancreatic carcinoma formation 
and progression in vivo using mouse models. Future studies can be performed to 
cross PHLPP1 or PHLPP2 knockout mice with KRas activating mutant mice in 
order to develop a working mouse model where the effect of PHLPP-loss in 
pancreatic will be monitored on the background of KRas activation. Since only 
KRAS mutation is needed to begin the process of PanIN development, it is 
feasible that elimination of tumor suppressor PHLPP would accelerate pancreatic 
tumorigenesis in these mouse models. Additional studies on signaling activation 
as the result of PHLPP-loss will help to identify potential therapeutic targets in 
pancreatic cancer.  
As previously stated, late stage diagnosis and the aggressiveness of 
pancreatic carcinoma, PDAC patients have a very low survival rate [124, 168]. 
The treatment options for PDAC are few and surgical resection is nearly 
impossible for the average patient [169]. Understanding the molecular 
mechanism leading to EMT and progression of PDAC potentially has a long 
lasting benefit in creating new treatment strategies, therapeutic targets, and even 
gene editing techniques. In this study, we provide the first strong evidence 
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supporting a tumor suppressor role of PHLPP in pancreatic cancer. Moreover, 
our finding that decreased PHLPP expression promotes EMT and cell motility 
through the possibility of inhibiting lysosome degradation of integrin proteins 
identifies a novel mechanism by which PHLPP suppresses oncogenic signaling. 
Further studies are warranted to further elucidate how PHLPP controls the 
protein expression of integrin through Akt activity. The ramifications of future 
studies would not only benefit pancreatic cancer but possibly contribute to 
carcinoma knowledge across all cancer types as well as auto-immune disorders, 
aging related diseases, diabetes, obesity, and other PI3K/Akt and Raf/MEK/ERK 
pathway related diseases.  Taken together, our study highlights the importance 
of future studies to further explore the possibility of using PHLPP as a diagnostic 
marker and a chemotherapeutic target in pancreatic cancer. 
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Appendix 
List of Abbreviations 
BA: Bafilomycin A 
CAF: Cancer-associated fibroblast 
CQ: Chloroquine 
DHH: Desert hedgehog 
ECM: Extracellular matrix 
EGFR: Epidermal growth factor receptor 
EMT: Epithelial-mesenchymal transition 
FBS: Fetal bovine serum 
GSK-3β Glycogen synthease kinase 3β  
HGF: Hepatocyte growth factor 
Hh: Hedgehog  
IF: Immunofluorescence 
IGF-1: Insulin-like growth factor 1 
IHH: Indian hedgehog 
IRS: Insulin receptor substrate 
MET: Mesenchymal-epithelial transition 
PanIN: Pancreatic intraepithelial neoplasia 
PDAC: Pancreatic ductal adenocarcinoma  
PEI: Polyethylenimine 
PHLPP: PH domain leucine-rich-repeats protein phosphatase 
PI3K: Phosphatidylinositol-3-kinases 
PKC: Protein kinase C 
PTC: Patched   
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qRT-PCR: Quantitative real-time PCR 
RTK: Receptor tyrosine kinase 
SCOP: Suprachiasmatic nucleus oscillatory protein 
SHH: Sonic hedgehog 
SMO: Smoothened 
TGF-β: Transforming growth factor β 
TIRF: Total internal reflection fluorescence 
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